Avgerinos I, Karagiannis T, Kakotrichi P, et al. - Treatment with sotagliflozin in patients with type 2 diabetes mellitus resulted in decrease in blood glucose, body weight and systolic blood pressure, as well as exerted a beneficial impact on heart failure and myocardial infarction. An overall safety profile comparable to other SGLT-2 inhibitors was displayed by sotagliflozin.

• Randomized controlled trials (RCTs) comparing sotagliflozin with placebo or other antidiabetic agents for type 2 diabetes were identified from Medline, Embase, the Cochrane Library, and grey literature sources.

• A meta-analysis with 11 RCTs including 16,411 participants was conducted.

• Relative to placebo, sotagliflozin decreased HbA1c [ WMD(weighted mean difference) −0.42 %], body weight (WMD –1.33 kg) and systolic blood pressure (WMD −2.44 mmHg).

• No difference was observed against other active comparators.

• Sotagliflozin treatment caused decrease in myocardial infarction (OR [odds ratio] 0.72) and heart failure (OR 0.68) vs placebo, and exerted a neutral impact on all-cause mortality, cardiovascular mortality, and stroke.

• Sotagliflozin was safe in terms of incidence of serious adverse events, hypoglycemia, and diabetic ketoacidosis.

• Nevertheless, increased incidence of diarrhea, genital infections, and volume depletion events was reported with sotagliflozin use.